Edition:
United Kingdom

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

57.80USD
21 Sep 2018
Change (% chg)

$-1.20 (-2.03%)
Prev Close
$59.00
Open
$58.80
Day's High
$59.25
Day's Low
$57.15
Volume
419,170
Avg. Vol
151,051
52-wk High
$68.15
52-wk Low
$40.75

Chart for

About

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.... (more)

Overall

Beta: --
Market Cap(Mil.): $4,359.11
Shares Outstanding(Mil.): 78.97
Dividend: --
Yield (%): --

Financials

  FGEN.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.92 -- --
ROI: -28.39 1.79 14.61
ROE: -58.84 3.28 16.33

Boost for 'made in China' medicine as Chi-Med wins key approval

LONDON Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

05 Sep 2018

UPDATE 1-Boost for "made in China" medicine as Chi-Med wins key approval

* Green light shows growing strength of Chinese biotech (Updates with CEO interview, latest shares, background)

05 Sep 2018

Boost for "made in China" medicine as Chi-Med wins key approval

LONDON, Sept 5 Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

05 Sep 2018

BRIEF-FibroGen Reports Q1 Loss Per Share $0.50

* Q1 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S

09 May 2018

BRIEF-Fibrogen Inc CEO's 2017 Compensation Was $7.1 Million

* FIBROGEN INC SAYS CEO THOMAS B. NEFF'S 2017 TOTAL COMPENSATION WAS $7.1 MILLION VERSUS $5.2 MILLION IN 2016 – SEC FILING Source text (https://bit.ly/2Hpk39x) Further company coverage:

24 Apr 2018

Earnings vs. Estimates